EKTA-B Stock Analysis: Elekta (publ) | ST
Medical Devices | ST, Sweden | Market Cap: 19.200m SEK | 12M Return: 9.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 63.0M
EPS Trend: -74.1%
Qual. Beats: -1
Rev. Trend: -59.2%
Qual. Beats: -2
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Elekta AB (publ) is a Sweden-based medical technology company founded in 1972 and headquartered in Stockholm, specializing in clinical solutions for cancer treatment and brain disorders. Its product portfolio spans linear accelerators and radiation therapy systems (including the Elekta Unity MR-guided linac, Versa HD, and Infinity), the Leksell Gamma Knife stereotactic radiosurgery platform, a broad brachytherapy line (such as Elekta Studio, Flexitron afterloaders, and the Venezia applicator for cervical cancer), and the Elekta ONE oncology software suite. The company also sells neurosurgery equipment (Leksell Vantage), the Kaiku digital health platform for personalized cancer care, veterinary radiation solutions, and an extensive Elekta Care services program covering maintenance, training, and clinical support. Elekta operates globally across the Americas, Europe, the Middle East, Africa, and Asia Pacific, serving radiation oncology providers, neurosurgery centers, and veterinary clinics as a dedicated hardware-and-software vendor within the broader radiotherapy and oncology equipment market.
- Linear accelerator orders track global hospital capital spending cycles
- Elekta ONE software suite drives recurring service revenue growth
- Varian and Siemens competition pressures radiation oncology market share
| Net Income: -519.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 4.14 > 1.0 |
| NWC/Revenue: -11.73% < 20% (prev 5.93%; Δ -17.66% < -1%) |
| CFO/TA 0.09 > 3% & CFO 2.46b > Net Income -519.0m |
| Net Debt (5.16b) to EBITDA (1.75b): 2.95 < 3 |
| Current Ratio: 0.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (383.6m) vs 12m ago 0.36% < -2% |
| Gross Margin: 37.38% > 18% (prev 37.45%; Δ -0.07% > 0.5%) |
| Asset Turnover: 59.78% > 50% (prev 62.18%; Δ -2.40% > 0%) |
| Interest Coverage Ratio: 2.30 > 6 (EBIT TTM 855.0m / Interest Expense TTM 371.0m) |
| A: -0.07 (Total Current Assets 13.1b - Total Current Liabilities 15.1b) / Total Assets 27.0b |
| B: 0.19 (Retained Earnings 5.21b / Total Assets 27.0b) |
| C: 0.03 (EBIT TTM 855.0m / Avg Total Assets 28.0b) |
| D: 0.36 (Book Value of Equity 7.10b / Total Liabilities 19.8b) |
| Altman-Z'' = 0.74 = B |
| DSRI: 0.98 (Receivables 7.04b/7.71b, Revenue 16.7b/18.0b) |
| GMI: 1.00 (GM 37.45% / 37.38%) |
| AQI: 0.96 (AQ_t 0.45 / AQ_t-1 0.47) |
| SGI: 0.93 (Revenue 16.7b / 18.0b) |
| TATA: -0.11 (NI -519.0m - CFO 2.46b) / TA 27.0b) |
| Beneish M = -3.12 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at SEK 51.40 with a total of 372,153 shares traded. Over the past week, the price has changed by -1.72%, over one month by -3.38%, over three months by -6.63% and over the past year by +9.48%.
Current recommended Stop Loss: 49.10 (which is 4.5% or 1.4 ATR below the current price).
Elekta (publ) has no consensus analysts rating.
P/E Forward = 13.9082
P/S = 1.1484
P/B = 2.8153
P/EG = 0.2754
Revenue TTM = 16.7b SEK
EBIT TTM = 855.0m SEK
EBITDA TTM = 1.75b SEK
Long Term Debt = 3.38b SEK (from longTermDebt, last quarter)
Short Term Debt = 3.19b SEK (from shortTermDebt, last quarter)
Debt = 8.35b SEK (from shortLongTermDebtTotal, last quarter) + Leases 1.01b
Net Debt = 5.16b SEK (calculated: Debt 8.35b - CCE 3.19b)
Enterprise Value = 24.4b SEK (19.2b + Debt 8.35b - CCE 3.19b)
Interest Coverage Ratio = 2.30 (Ebit TTM 855.0m / Interest Expense TTM 371.0m)
EV/FCF = 11.61x (Enterprise Value 24.4b / FCF TTM 2.10b)
FCF Yield = 8.61% (FCF TTM 2.10b / Enterprise Value 24.4b)
FCF Margin = 12.55% (FCF TTM 2.10b / Revenue TTM 16.7b)
Net Margin = -3.10% (Net Income TTM -519.0m / Revenue TTM 16.7b)
Gross Margin = 37.38% ((Revenue TTM 16.7b - Cost of Revenue TTM 10.5b) / Revenue TTM)
Gross Margin QoQ = 39.52% (prev 35.10%)
Tobins Q-Ratio = 0.90 (Enterprise Value 24.4b / Total Assets 27.0b)
Interest Expense / Debt = 4.45% (Interest Expense 371.0m / Debt 8.35b)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = 641.2m (EBIT 855.0m * (1 - 25.00%))
Current Ratio = 0.87 (Total Current Assets 13.1b / Total Current Liabilities 15.1b)
Debt / Equity = 1.18 (Debt 8.35b / totalStockholderEquity, last quarter 7.10b)
Debt / EBITDA = 2.95 (Net Debt 5.16b / EBITDA 1.75b)
Debt / FCF = 2.46 (Net Debt 5.16b / FCF TTM 2.10b)
Total Stockholder Equity = 8.15b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.86% (Net Income -519.0m / Total Assets 27.0b)
RoE = -6.37% (Net Income TTM -519.0m / Total Stockholder Equity 8.15b)
RoCE = 7.41% (EBIT 855.0m / Capital Employed (Equity 8.15b + L.T.Debt 3.38b))
RoIC = 4.50% (NOPAT 641.2m / Invested Capital 14.2b)
WACC = 7.30% (E(19.2b)/V(27.5b) * Re(9.03%) + D(8.35b)/V(27.5b) * Rd(4.45%) * (1-Tc(0.25)))
Discount Rate = 9.03% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 29.81 | Cagr: 0.17%
[DCF] Terminal Value 77.97% ; FCFF base≈1.68b ; Y1≈1.93b ; Y5≈2.84b
[DCF] Fair Price = 102.2 (EV 42.7b - Net Debt 5.16b = Equity 37.5b / Shares 367.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -74.07 | EPS CAGR: -41.80% | SUE: -0.93 | # QB: -1
Revenue Correlation: -59.19 | Revenue CAGR: -1.71% | SUE: -1.80 | # QB: -2
EPS current Quarter (2026-07-31): EPS=0.50 | Chg30d=-27.97% | Revisions=-25% | Analysts=5
EPS next Quarter (2026-10-31): EPS=0.86 | Chg30d=+23.04% | Revisions=+25% | Analysts=5
EPS current Year (2027-04-30): EPS=3.93 | Chg30d=+2.14% | Revisions=-36% | GrowthEPS=+61.7% | GrowthRev=+4.0%
EPS next Year (2028-04-30): EPS=4.31 | Chg30d=-1.82% | Revisions=-50% | GrowthEPS=+9.8% | GrowthRev=+4.1%
[Analyst] Revisions Ratio: -44% (up=6, down=18)